Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
TVTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Travere Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Travere Therapeutics, Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How TVTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-23 | FILSPARI (sparsentan) | Phase 3 data presentation | Phase 3 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| FILSPARI | |||
| Tiopronin products |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| L-Citrulline Small MoleculesNCT06989567 | Sickle Cell Disease | Phase 3 | NOT YET_RECRUITING | 120 | Jun 1, 2029 | ||||||
| Pegtibatinase Enzyme Replacement Therapies (ERT)NCT06431893 | Homocystinuria | Phase 3 | ENROLLING BY_INVITATION | 209 | Aug 1, 2030 | ||||||
| Sparsentan Small MoleculesMarketedNCT05856760 | Immunoglobulin A Nephropathy | Approved | COMPLETED | 478 | Oct 25, 2024 | ||||||
| Sparsentan Small MoleculesMarketedNCT03493685 | Focal Segmental Glomerulosclerosis | Approved | COMPLETED | 438 | Mar 19, 2026 | ||||||
| RE-021, sparsentan Small MoleculesMarketedNCT01613118 | Focal Segmental Glomerulosclerosis | Approved | COMPLETED | 109 | Mar 25, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every TVTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| FILSPARI PriorityAccelerated | IgA nephropathy | Phase 2 | 2026-10-02 | complete proteinuria remission: 75%; e GFR decline: -1.75 mL/min/1.73 m²; chronic e GFR slope: -1.11 mL/min/1.73 m²/year; total e GFR slope: -1.54 mL/min/1.73 m²/year; FSGS complete proteinuria remission: 20%; FSGS partial remission: 79%Read More | Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dube Eric MDirector, Officer (CHIEF EXECUTIVE OFFICER) | Option | 43,735 476,621 held | $26.88 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TVTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 3.6 % (12.5 %) | 208.61 M | 3.54 M | -5.59% ( -209.66 K) |
Ownership Trends
TVTX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How TVTX ranks across every disease it competes in
TVTX News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announced inducement equity grants for 20 new employees on November 10, 2026. The grants consist of 65,520 restricted stock units (RSUs) that vest over four years. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract new talent to the company.
Read more →Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics announced its participation in several upcoming investor conferences. Management will present at the Guggenheim Global Healthcare Conference on November 10, 2026, and at other events throughout November. Live webcasts of the presentations will be available on the company's investor page.
Read more →Travere Therapeutics Reports Third Quarter 2026 Financial Results
Travere Therapeutics reported strong third quarter 2026 results with FILSPARI sales of $200 million, marking a 120% increase year-over-year. The company is advancing its Phase 3 HARMONY Study for pegtibatinase, with topline results expected in late 2027. Civorebrutinib's IND submission is anticipated by year-end, supporting its development in immune-mediated kidney diseases.
Read more →Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Therapeutics will announce its third quarter 2026 financial results on November 2, 2026. The company plans to hold a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the information through the company's website.
Read more →Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Travere Therapeutics presented new biomarker data from the Phase 3 PROTECT Study at ASN Kidney Week, indicating that FILSPARI (sparsentan) may modify disease pathophysiology in IgA nephropathy (IgAN). The study showed that FILSPARI achieved greater reductions in kidney inflammation biomarkers compared to irbesartan, supporting its use as a first-line treatment. These findings align with previous PROTECT results demonstrating superior proteinuria reduction.
Read more →Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Travere Therapeutics announced it will present nine new data presentations at ASN Kidney Week 2026, including five oral presentations. The data focuses on the efficacy of FILSPARI® (sparsentan) in treating patients with IgA nephropathy and focal segmental glomerulosclerosis. The final SPARTAN analysis is expected to provide significant insights into the treatment's potential.
Read more →Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics has received a Notice of Allowance from the USPTO for its patent application concerning methods of using FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS). This patent, once issued, will provide U.S. patent protection for specific applications of the drug, potentially strengthening the company's market position in the treatment of kidney diseases.
Read more →Travere Therapeutics Announces Planned Chief Executive Officer Transition
Travere Therapeutics announced the resignation of CEO Eric Dube, who is stepping down to focus on his health and family. The Board of Directors has appointed Bradley L. Campbell, the former CEO of Amicus Therapeutics, as the new president and CEO. This leadership change reflects the company's commitment to continuity and experienced management.
Read more →Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
Travere Therapeutics will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The presentation will be accessible via a live webcast on the company's investor page, with a replay available for 30 days post-event. This engagement underscores Travere's commitment to addressing the needs of the rare disease community.
Read more →Travere Therapeutics Reports Second Quarter 2026 Financial Results
Travere Therapeutics has reported its financial results for the second quarter of 2026, highlighting a strong performance that indicates a period of growth for the company. CEO Eric Dube emphasized the disciplined execution of their strategies, which has contributed to their success. The report suggests optimism for both immediate and future prospects.
Read more →Travere Therapeutics to Report Second Quarter 2026 Financial Results
Travere Therapeutics, Inc. has announced that it will report its second quarter 2026 financial results on August 4, 2026, after U.S. markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a business update. Archived access to the call will be available for 30 days on their website.
Read more →Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Travere Therapeutics has announced the planned retirement of its Chief Research Officer in 2027. This decision marks a significant transition for the company as it prepares for future leadership changes. The announcement comes as part of the company's ongoing strategic planning efforts.
Read more →Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study at the 63rd European Renal Association Congress. This study highlights the ongoing research into treatments for rare kidney diseases. Additionally, the company announced an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a promising BTK inhibitor.
Read more →Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics has entered into an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a potential best-in-class BTK inhibitor aimed at treating rare kidney diseases. This partnership may enhance the development and commercialization of the drug in targeted markets. Further details about the agreement and its implications for both companies are yet to be disclosed.
Read more →